Blocking IL-4 and IL-13 in people with house dust mite–triggered allergic asthma receiving dupilumab
Mechanistic clinical trial of blocking the IL-4/13 axis in asthmatics precision phenotyped in an aeroallergen challenge chamber before, during and after receipt of dupilumab
This tests whether blocking IL-4 and IL-13 with dupilumab reduces allergy and asthma reactions in people with house dust mite–linked allergic rhinitis and asthma.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11386758 on NIH RePORTER |
What this research studies
You would join a randomized, double-blind trial where some participants receive dupilumab and others receive placebo. Before, during, and after treatment you will enter an aeroallergen challenge chamber to receive controlled house dust mite exposures so researchers can watch how your symptoms change. The team will measure breathing, allergy symptoms, and airway samples to study inflammation and airway lining (epithelial) integrity and to classify response patterns like adaptive or resilient. Results will be used to link these biological measures to who responds best to blocking IL-4/IL-13.
Who could benefit from this research
Good fit: Adults with house dust mite–associated perennial allergic rhinoconjunctivitis and asthma who can safely undergo controlled allergen challenge visits are the ideal candidates.
Not a fit: People without house dust mite allergy, those whose asthma is not driven by allergies, or those who cannot attend challenge chamber visits are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, this could reduce allergy and asthma symptoms and help predict which patients are most likely to benefit from dupilumab.
How similar studies have performed: Dupilumab, which blocks IL-4 and IL-13, has already helped many people with asthma and atopic disease, but using an aeroallergen challenge chamber to connect responses to airway biomarkers is a novel mechanistic approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Ahuja, Sunil K — University of Texas Hlth Science Center
- Study coordinator: Ahuja, Sunil K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.